Bifunctional Biologic Gets Orphan Drug Status for Paroxysmal Nocturnal Hemoglobinuria
The FDA has granted Orphan Drug designation to KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Source: empr.com
📰 Frederick Beddingfield News
Page 2 - Frederick Beddingfield News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Frederick Beddingfield. Real-time updates on events, politics, business and more.
Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
/PRNewswire/ -- Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated...
United States United Kingdom South Korea Frederick Beddingfield Kira Pharmaceuticals Drug Administration
Source: prnewswire.com
Bifunctional Biologic Gets Orphan Drug Status for Paroxysmal Nocturnal Hemoglobinuria
The FDA has granted Orphan Drug designation to KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Source: empr.com
Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China
Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China News provided by Share this article Share this article CAMBRIDGE, Mass. and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the addition of three seasoned pharmaceutical leaders, Kathy He, Richar...
Source: prnewswire.com
Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated...
United Kingdom United States Frederick Beddingfield Kira Pharmaceuticals Chief Executive Officer Healthcare Conference
Source: prnewswire.com
Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
Share this article Share this article CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 million Series B+ financing. The financing was co-led by RA Capital Management and Vivo Capital, with participation from Foresite Capital and APlus Partners. Existing investors, includi...
Source: prnewswire.com